Host chromatin DNA (DNA)

Host chromatin DNA serves as the fundamental repository of genetic information within the nucleus of eukaryotic cells, organized into a complex structure with histone proteins (NIH, 2023). It is a critical therapeutic target, particularly in oncology, where drugs aim to disrupt the integrity or function of DNA to halt the proliferation of malignant cells (National Cancer Institute, 2022). Various classes of chemotherapeutic agents, such as alkylating agents (e.g., Cisplatin) and intercalators (e.g., Doxorubicin), interact directly with the DNA double helix to induce structural damage or inhibit essential enzymes like topoisomerases (StatPearls, 2023). Beyond cancer, host DNA is involved in the life cycles of certain viruses that integrate their genetic material into the host genome, and it can also be a target in autoimmune conditions like systemic lupus erythematosus where anti-DNA antibodies are present (PubMed, 2021). However, because DNA is universal to all cells, targeting it often results in significant off-target effects and systemic toxicity, including myelosuppression and secondary malignancies (American Cancer Society, 2023). Modern approaches seek to increase the selectivity of DNA-damaging agents or exploit specific DNA repair deficiencies, such as BRCA mutations, in tumor cells to improve therapeutic outcomes (Nature Reviews Cancer, 2020).

Other names

Genomic DNANuclear DNAChromosomal DNADeoxyribonucleic acidHost genome

Drugs targeting host chromatin DNA typically act through covalent binding (alkylation), intercalation between base pairs, or induction of single- and double-strand breaks (StatPearls, 2023). These actions disrupt DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing cells (National Cancer Institute, 2022).